Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) is the
consummate success story for targeted therapy, yet relapse is a nearly inevitable …

Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …

Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized
by the translocation t (9; 22), coding for the chimeric protein BCR-ABL. The development of …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …

Chronic myeloid leukemia (CML) is a classical example of stem cell cancer since it arises in
a multipotent hematopoietic stem cell upon the acquisition of the t (9; 22) chromosomal …

Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder characterized by
the presence of a fusion oncogene BCR‐ABL, which encodes a protein with constitutive TK …

BCR-ABL tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia
(CML), but they rarely eliminate CML stem cells. Disease relapse is common upon therapy …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by a
chromosome translocation that generates the Bcr-Abl oncogene encoding a constitutive …

Targeted therapies of chronic myeloid leukemia (CML) using tyrosine kinase inhibitors (TKI)
have profoundly changed the natural history of the disease with a major impact on survival …